Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: ekn who wrote (117187)	1/27/2000 6:05:00 PM
From: ekn	Read Replies (1) \| Respond to of 119973

Here is some DD on IMDS. These are clinical images from one of the hospitals they are currently participating in trial for FDA approval. Notice the remarkable technology, the clear, concise pictures. the technology is not limited to breast cancers. This technology using "flourescent markers" could "revolutionize diagnostic screening" for various cancers. This market is measured in BILLIONS. Note that this technology would work in unison with other diagnostic tools so there is no competition. Women will demand this technology once FDA approval is accepted as current mammography is very painful and loaded with radiation, unlike the laser scan. Since this is a diagnostic product it would be evaluated under "fast track" which puts approval @ 90 days or less upon submission. IMO, I truly believe upon FDA approval, IMDS will move into the 20-30$ range. That's my opinion. imds.com